Teligent, Inc. announces the opening of a product development laboratory in Estonia.
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, announced that it has opened a pharmaceutical Product Development laboratory in Estonia. The GMP-compliant lab will support the development of topical and injectable pharmaceutical products for the company’s North American markets.
The 3,000-square foot facility also includes administrative space for quality assurance and supply chain employees who oversee the company’s third-party contract manufacturing activities around the world.
“We are excited to strengthen our R&D capabilities through the opening of this product development lab in Estonia,” commentedJason Grenfell-Gardner, President and CEO of the company. “We are impressed by the caliber of scientific talent available in the country, and look forward to this lab working closely with our R&D colleagues in New Jersey.”
The company established its operation in Estonia in 2015, where it has been managing logistics and supply relationships between third-party suppliers and the US and Canadian markets. Grenfell-Gardner concluded, ”The opening of this lab for analytical method and formulation work is the next step in our journey to build pharmaceutical capabilities in our Estoniabusiness.”
To view the full press release, click here.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
